Opinion|Videos|February 9, 2026
Data from PALOMA-3 for Subcutaneous Amivantamab in EGFR-Mutated NSCLC
Author(s)Narjust Florez, MD
New data show subcutaneous amivantamab matches IV efficacy, cuts infusion reactions and steroid prep, and slashes clinic time and costs.
Advertisement
Episodes in this series
Narjust Florez, MD, summarizes clinical data from the phase 3 PALOMA-3 study (NCT05388669) evaluating a amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) in EGFR-mutated non–small cell lung cancer (NSCLC). Florez highlights pharmacokinetic comparability, administration time, and safety findings relative to the intravenous formulation of amivantamab. She contextualizes these data within the broader treatment landscape, focusing on potential implications for infusion-related reactions and overall treatment delivery.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.
ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.
PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
3
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
4
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
5